Several prediction models have been developed to estimate the outcomes of prostate biopsies. Most of these tools were designed for use with Western populations and have not been validated across different ethnic groups. Therefore, we evaluated the predictive value of the Prostate Cancer Prevention Trial (PCPT) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators in a Chinese cohort. Clinicopathological information was obtained from 495 Chinese men who had undergone extended prostate biopsies between January 2009 and March 2011. The estimated probabilities of prostate cancer and high-grade disease (Gleason .6) were calculated using the PCPT and ERSPC risk calculators. Overall measures, discrimination, calibration and clinical usefulness were assessed for the model evaluation. Of these patients, 28.7% were diagnosed with prostate cancer and 19.4% had high-grade disease. Compared to the PCPT model and the prostate-specific antigen (PSA) threshold of 4 ng ml 21 , the ERSPC risk calculator exhibited better discriminative ability for predicting positive biopsies and high-grade disease (the area under the curve was 0.831 and 0.852, respectively, P,0.01 for both). Decision curve analysis also suggested the favourable clinical utility of the ERSPC calculator in the validation dataset. Both prediction models demonstrated miscalibration: the risk of prostate cancer and high-grade disease was overestimated by approximately 20% for a wide range of predicted probabilities. In conclusion, the ERSPC risk calculator outperformed both the PCPT model and the PSA threshold of 4 ng ml 21 in predicting prostate cancer and high-grade disease in Chinese patients. However, the prediction tools derived from Western men significantly overestimated the probability of prostate cancer and high-grade disease compared to the outcomes of biopsies in a Chinese cohort.
INTRODUCTION
Prostate cancer is the second most frequently diagnosed cancer among men worldwide, with an estimated 914 000 new cases in 2008.
1 There are, however, striking geographical variations in the incidence rates of prostate cancer globally. For instance, the recorded rate (per 100 000) of US blacks is 178.8, which represents a 25-fold increase compared to the rate of prostate cancer in Shanghai (6.9).
1 One important reason for the large difference in prostate cancer incidence is the widespread use of prostate-specific antigen (PSA) testing in Western countries. 2, 3 In addition, accumulating evidence suggests that differences in lifestyle and genetic susceptibility are largely responsible for the observed regional/ethnic differences in prostate cancer risk. 4 PSA has been commonly used by clinicians to estimate the probability of prostate cancer and to counsel patients regarding subsequent biopsies. However, the appropriate PSA threshold above which further evaluation with a biopsy of the prostate should be recommended to exclude prostate cancer remains controversial. [5] [6] [7] PSA levels are a continuous parameter, so the higher the PSA value is, the higher the risk of prostate cancer. To overcome the drawbacks of PSA testing, several prediction models have been developed to assist in better risk classification. In 2006, investigators from the Prostate Cancer Prevention Trial (PCPT) reported a risk calculator based on age, race, PSA, digital rectal examination (DRE), family history and the history of a previous negative prostate biopsy. 8 Similarly, the European Randomized Study of Screening for Prostate Cancer (ERSPC) section in Rotterdam constructed another risk calculator that includes PSA, DRE, transrectal ultrasound (TRUS) findings and prostate volume. 9 The performance of these two risk calculators in Western populations has been assessed by external validation. [10] [11] [12] [13] However, the usefulness of these prediction tools in the Chinese population remains undefined. To evaluate this, we identified a cohort of patients who had undergone systematic prostate biopsies with a minimum of 10 cores at our institution. The predictive value of these two risk calculators was then externally validated and compared according to the standard framework. 14 
MATERIALS AND METHODS

Patient population and risk calculations
We retrospectively reviewed the medical records of patients who had undergone TRUS-guided prostate biopsies at Fudan University Shanghai Cancer Center between January 2009 and March 2011. The indications of prostate biopsy were a PSA level greater than 4 ng ml 21 and/or suspicious results from a DRE or a TRUS. Of 609 assessable patients, 114 were excluded because of extreme variables (PSA level .50 ng ml 21 or prostate volume .150 ml) or rare types of prostate cancer. Therefore, a total of 495 cases, including 402 initial biopsies and 93 repeat biopsies, were available for further analysis. Initial biopsies and repeat biopsies were performed according to the institution's protocol with a minimum of 10 and 12 cores, respectively. All specimens were independently evaluated by two genitourinary pathologists for diagnoses and Gleason scores.
Two formulas from PCPT to predict the probability of prostate cancer and high-grade disease (Gleason .6) were obtained from the authors' web site. 8 Individual risk estimations using the ERSPC model were calculated using online calculators 3 and 5 for patients undergoing initial biopsies and repeat biopsies, respectively. 9 Variables were coded and transformed according to the requirements of the ERSPC and PCPT risk calculators. To better define the value of the risk calculators, PSA levels were used as a reference prediction tool in the analyses.
This study was approved by the institutional review board, and written inform consent was obtained from each patient.
Statistical analyses
Descriptive statistics of the cohort were reported and compared to those of the datasets used to develop the risk calculators. Multivariate logistic regression analyses were carried out to assess the predictive variables. For high-grade disease, a multinomial model was applied with three potential outcomes-no cancer, low-grade cancer and high-grade cancer. The performance of each risk calculator was evaluated statistically on the basis of its discrimination, calibration and clinical usefulness. 14 The area under the receiver operating characteristic (ROC) curve was used to compare the ability to discriminate between patients with prostate cancer from those without prostate cancer. The comparisons of the areas under the curve (AUCs) were made using the method of DeLong et al. 15 Calibration refers to a measure of the level of agreement between the observed outcomes in the validation cohort (n5495) and the predicted probabilities calculated using the risk calculators. The extent of over/underestimation comparing the observed rates to the predicted rates was explored graphically using calibration plots. Calibration-in-the-large was evaluated by fitting a logistic regression model with the predictions of the model as an offset variable. The intercept, which ideally should be zero, indicates whether the predictions were systematically too low or too high. The calibration slope reflects the average effects of the predictors in the model and was estimated in a logistic regression model with the logit of the model predictions as the only predictor. For a perfect model, the slope would be equal to 1. Clinical utility was assessed using decision curve analyses. 16 These analyses estimate the 'net benefit' of prediction models by summing the benefits (true-positive biopsies) and subtracting the negative outcomes (false-positive biopsies). The latter are weighted by a factor related to the relative harm of a missed cancer diagnosis versus an unnecessary biopsy. The weighting is derived from the threshold probability of prostate cancer at which a patient would opt for a biopsy, which can vary from patient to patient. When interpreting decision curves, the model with the highest net benefit at a particular threshold probability should be chosen. For all analyses, two-sided P values ,0.05 were considered to be statistically significant. Statistical analyses were performed using R 2.13.0 software (R Foundation for Statistical Computing, Vienna, Austria). Table 1 shows the clinicopathological characteristics of the participants enrolled in the current study and those from the ERSPC and PCPT datasets 8, 9 (Roobol MJ, pers. commun.). The age distributions were similar among the three patient cohorts. The study population from our institution, however, had the highest median PSA levels. The differences in baseline characteristics were the most obvious between patients from our cohort and those from the PCPT study. Men who were referred to our centre seldom had a family history of prostate cancer but had a high probability of abnormal DRE findings.
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RESULTS
Multivariate logistic regression analyses of predictors were performed for biopsy outcomes ( Table 2) . Because of its extremely low prevalence (0.6%), family history was not included as a prognostic factor in this cohort. Statistical analyses revealed that age, PSA levels, prostate volume and abnormal DREs were significant prognostic factors for prostate cancer and high-grade disease.
External validations of the ERSPC and PCPT risk calculators were performed according to a recently described framework.
14 First, the detailed performance statistics of each prediction model were assessed (Table 3) . Second, the ROC curves of the risk calculators and the 4 ng ml 21 PSA threshold were compared. Various cut-offs and their corresponding test sensitivities and specificities were listed for the convenience of clinical practice. Third, calibration plots were drawn to demonstrate the discrepancies between the predicted and the observed probabilities over from 0% to 100%. Finally, the clinical utility of the prediction models was assessed using decision curve analysis. The net benefit and net reduction of each model at various thresholds was calculated by subtracting that of the traditional PSA cut-off.
In this cohort, the AUC for PSA to discriminate any prostate cancer and high-grade disease were 0.75 (0.70-0.80) and 0.75 (0.69-0.81), respectively. For estimating the probability of a positive biopsy, the ERSPC risk calculator exhibited a higher AUC than either the PCPT model or the PSA threshold of 4 ng ml 21 (both P,0.01, as shown in Figure 1a ). However, the calibration plots of the two models were far from ideal (Figure 2a and b) . The risk of malignant disease was overestimated by more than 20% for predicted probabilities between 40% and 80%. The decision curve analysis indicated that the ERSPC model outperformed both the PCPT model and the PSA criterion (Figure 3a  and b) . Similarly, the ERSPC model also showed better discriminative ability (both P,0.01, as shown in Figure 1b ) and clinical usefulness (Figure 3c and d) than both the PCPT model and the PSA criterion in predicting high-grade cancer. However, the predicted probabilities provided by the two models were approximately 20% higher than the observed frequency in a wide range of patients (Figure 2c and d) .
DISCUSSION
By incorporating several predictors, the ERSPC and PCPT risk calculators were developed to facilitate making appropriate decisions regarding prostate biopsies. 8, 9 The two prediction models have been previously applied to Western populations, [10] [11] [12] [13] but their performance in Chinese men had been unknown. The objective of this study was to externally validate the ERSPC and PCPT risk calculators in a Chinese cohort referred to a regional cancer centre. For predicting the risk of positive biopsy, the ERSPC model showed better discriminative ability and clinical utility than the PCPT risk calculator and the use of PSA levels alone. However, the prediction tool strongly overestimated the probability of prostate cancer in the study cohort. Similar findings were observed after applying the two models for estimating the probability of high-grade disease. Ethnic variation is an important determinant of the incidence and characteristics of prostate cancer. 4 The standardized incidence (per 100 000 individuals) of prostate cancer reported between 2003 and 2007 was 230 for African American men and 81 in Asian American and Pacific Islander males. 18 Even among Asian Americans, the incidence of prostate cancer varies greatly, with the highest rate observed in Filipinos and the lowest in Koreans. 19 Although PSA screening markedly influences the incidence of prostate cancer, it cannot account for all of the discrepancies between different ethnical groups. We found the frequency of prostate cancer in radical cystoprostatectomy specimens to be only 3.3% (3/92) in Chinese men, which is much lower than that reported in Western countries. 20 A recent study provided further evidence about distinctive genomic alterations between prostate cancers in individuals from Chinese men and men from Western populations. Certain somatic genomic changes that are commonly found in Western cases are only rarely observed in Chinese patients. 21 Different carcinogenic mechanisms may subsequently affect prostate cancer disease characteristics and warrant the ethnicbased management of prostate cancer.
Recently, Yoon et al. 22 validated the ERSPC risk calculator 3 in 602 Korean patients. The observed AUC was 0.88 (95% confidence interval (CI): 0.86-0.90), but the calibration plot showed remarkable miscalibration: the predicted probabilities were nearly 20% higher than the observed frequency for predictions from 30% to 90%. 22 Similar to these previous findings, we found that the prediction models derived from Western patients overrated the probability of prostate cancer and high-grade disease by approximately 20%. Because we used an extended 10 core biopsy in all patients, the observed overestimation of risk is unlikely to be due to missed cancer diagnoses by biopsies. Several reasons may account for the low probability of prostate cancer in this study cohort. First, although age, PSA level, prostate volume and DRE were identified as independent prognostic factors in both the validation and development sets, the strength of these associations may vary in different settings. In the ERSPC study, the effect of PSA levels on biopsy outcomes was greater under the 3 ng ml 21 threshold than at PSA levels above 3 ng ml 21 . 23 Furthermore, both TRUS and DRE significantly increased the detection rate of prostate cancer in subjects with PSA levels below 4 ng ml 21 . 24, 25 In our series, multivariate analysis demonstrated that the odds ratios of PSA and prostate volume were 4.09 and 0.17, respectively. In contrast, the effect measures of PSA and prostate volume in the ERSPC study were 42.8 and 0.02, respectively. 23 Therefore, the risk calculators derived from screening datasets may overestimate the effects of prognostic factors when applied to men with elevated PSA levels. Second, the diagnostic characteristics of the assessed predictors exhibited significant variation between different ethnic groups. Using a PSA level of 4.1 ng ml 21 as the threshold for biopsy, the sensitivity and the specificity of the test were 35% and 88%, respectively, in men over 60 years of age from a North American cohort. 5 However, similar criteria resulted in a sensitivity of 96% and a specificity of 14% in a cohort of 1236 Chinese patients. 6 From a mass screening study of Chinese individuals, Gao et al. 26 reported that the detection rate of prostate cancer was 14.8% in the PSA range of 4-10 ng ml 21 and 29% in the PSA range of 10-20 ng ml 21 . In contrast, similar criteria yielded an approximately twofold increase in the probability of prostate cancer in Americans. 27 A similar phenomenon was observed for abnormal DRE results: 52% of white, 58% of black and 34% of Asian/Pacific Islander men had a positive biopsy, which corresponds to an approximately 40% lower rate in Asians/Pacific Islanders when compared to white or black men. 28 The difference was more prominent in men with PSA levels less than 10 ng ml 21 and abnormal DRE findings. Indeed, in these individuals, the rate of prostate cancer diagnosis was 42.8%, 52.0% and 13.5% for white, black and Asian/Pacific Islander men, respectively. 28 Finally, the prognostic significance of PSA levels and DRE results may be limited in Chinese patients. Because PSA screenings are largely unavailable in China, many referral patients may have a history of chronic inflammation or benign prostate hyperplasia that subsequently results in elevated PSA levels and potentially contributes to abnormal DRE results.
Several studies have reported conflicting results. For example, Ito et al.
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had reported the probability of prostate cancer in a Japanese screening cohort that was observed over a 4-year period. Only men between the ages of 55 and 74 who had PSA levels less than 4 ng ml 21 and did not exhibit abnormal DRE results were initially enrolled. Interestingly, Ito et al. 29 found a similar risk of developing prostate cancer as that reported in Figure 1 ROC curves of the risk calculators and the PSA threshold of 4 ng ml 21 for prostate cancer (a) and high-grade disease (b) in the validation cohort (n5495). Pairwise comparisons of ROC curves are shown in the bottom-right corner of the figure. The table displays the sensitivity and specificity of each risk calculators at different cut-offs. For example, using the ERSPC risk calculator in this cohort, a cut-off of 30% corresponds to a sensitivity of 89.4% and a specificity of 49.0% in detecting prostate cancer. ERSPC, European Randomized Study of Screening for Prostate Cancer; PSA, prostate-specific antigen; ROC, receiver operating characteristic.
Validation of prostate cancer risk calculators in Chinese
the ERSPC study after adjusting for initial PSA levels. However, because of the relatively short follow-up period (4 years) of Ito et al. 's study, it is likely that their results actually reflect the probability of active prostate cancers becoming clinically detectable. As revealed by autopsy studies, the actual prevalence of prostate cancer is strikingly lower in Asian areas than in other parts of the world. 30, 31 Furthermore, the characteristics of the enrolled subjects varied between the Japanese and the Rotterdam cohort: 49.8% of the men in the Japanese study had initial PSA levels below 1 ng ml 21 , compared to only 25.9% for individuals from the Rotterdam cohort. 29 It is therefore difficult to observe significant differences between these relatively low-risk groups given the relatively short follow-up period.
Our results indicate that the ERSPC risk calculator exhibits superior discrimination and calibration than the PCPT model. One potential explanation for this observation is that the ERSPC model includes more predictive prognostic factors, such as prostate volume and TRUS findings. In contrast, the inclusion of family history did not enhance the predictive ability of the PCPT risk calculator, because only three patients from our cohort had a positive family history. This finding is similar to that from another population-based study in Shanghai, in which none of the 238 subjects reported a family history of prostate cancer. 32 Furthermore, the study population used to develop the PCPT risk calculator was quite different from our cohort. For instance, the percentage of men with PSA levels above 4 ng ml 21 was 92.7% in our study but only 11.4% in the PCPT cohort. Therefore, the observed lack of predictive ability may be largely due to the significant differences in patient characteristics between the population used to develop the PCPT risk calculator and the current cohort.
Our study had several limitations. First, because the variables and outcomes were retrospectively collected from a tertiary cancer centre, the results may have been influenced by the heterogeneity of patients, tumours and biopsy techniques. Second, most (92.7%) of the individuals enrolled in this study exhibited PSA values greater than 4 ng ml
21
. Thus, the performance of these risk calculators in Chinese men underwent PSA screen remains to be determined. Furthermore, the long-term outcomes of these risk calculators in Chinese prostate cancer patients should be determined because of possible distinctive disease characteristics observed in this population. Nevertheless, our study may provide a key step towards understanding the optimal prostate cancer management strategies in different ethnic groups.
In conclusion, compared to the PCPT risk calculator, the ERSPC model exhibited better discriminative ability for prostate cancer and high-grade disease in Chinese patients. However, the two prediction tools significantly overestimated the probability of biopsy outcome by approximately 20%. The underlying variations in carcinogenesis pathways between different ethnic groups require further investigation.
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